Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy

被引:4
|
作者
Mesia, R. [1 ]
Majem, M. [1 ]
Ginesta, M. P. Barretina [1 ]
Galiana, R. [2 ]
Manos, M. [3 ]
Guedea, F. [2 ]
Montes, A. [1 ]
Monner, A. [4 ]
Perez, J. [5 ]
Cardenal, F. [1 ]
机构
[1] Inst Catala Oncol Duran & Reynals, Dept Med Oncol, Lhospitalet De Llobregat 08907, Spain
[2] Inst Catala Oncol Duran & Reynals, Dept Radiat Oncol, Lhospitalet De Llobregat 08907, Spain
[3] Inst Catala Oncol Duran & Reynals, Dept ENT, Lhospitalet De Llobregat 08907, Spain
[4] Inst Catala Oncol Duran & Reynals, Dept Maxillofacial Surg, Lhospitalet De Llobregat 08907, Spain
[5] Inst Catala Oncol Duran & Reynals, Clin Invest Unit, Lhospitalet De Llobregat 08907, Spain
来源
CANCER RADIOTHERAPIE | 2008年 / 12卷 / 02期
关键词
unresectable squamous head and neck cancer; induction chemotherapy; hyperfractionated radiotherapy;
D O I
10.1016/j.canrad.2007.09.148
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. - The contribution of induction chemotherapy (CT) followed by hyperfractionated radiotherapy (hfRT) in unresectable squamous head and neck cancer has been evaluated in a single institution as an assistencial protocol. Patients and methods. - From March 1994 to June 2000 all consecutive patients with unresectable disease were treated with four courses of platin plus fluorouracil based CT followed by hfRT. Tumor resectability and response was assessed by a multidisciplinary committee. Results. - Ninety-nine patients (pts) were treated. All of them had stage IV-M0 disease: 67 T4, 88 N2-N3. Tumor location: 62 oropharynx, 22 hypopharynx, eight oral cavity and seven larynx. Tumor response at the end of treatment: 61 patients complete response, 17 partial response, two stable disease, 10 progressive disease and nine unevaluated. With a median follow-up of 70 months the 5-year loco-regional control and overall survival was 30.3% (95% CI: 21.9-38.6) and 21.6% (95% CI: 13.4-29.8), respectively. Loco-regional control and overall survival is significantly influenced by prior response to induction CT. Main grade 3-4 toxicity related to CT was stomatitis, but there were five patients with an ischemic event. Grade 3-4 acute toxicity related to hfRT: 47 stomatitis, 20 epithelitis. Chronic toxicity related to hfRT: six emergency tracheotomies due to laryngeal edema, five pneumonia and one mucous/soft-tissue necrosis. There were eight toxic related deaths. Conclusion. - Induction CT followed by hfRT might increase the overall survival rate in unresectable disease. HfRT resulted in a high rate of acute toxicity and its use would not be warranted in those patients with no response to induction CT who had a low probability of long-term control. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:88 / 95
页数:8
相关论文
共 50 条
  • [31] A non-randomised, single-centre comparison of induction chemotherapy followed by radiochemotherapy versus concomitant chemotherapy with hyperfractionated radiotherapy in inoperable head and neck carcinomas
    Graf, R
    Hildebrandt, B
    Tilly, W
    Riess, H
    Felix, R
    Budach, V
    Wust, P
    [J]. BMC CANCER, 2006, 6 (1)
  • [32] INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY IN ADVANCED HEAD AND NECK CANCER
    Karacetin, D.
    Okten, B.
    Maral, O.
    Incekara, O.
    Aslan, M.
    Aykanat, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 224 - 224
  • [33] A non-randomised, single-centre comparison of induction chemotherapy followed by radiochemotherapy versus concomitant chemotherapy with hyperfractionated radiotherapy in inoperable head and neck carcinomas
    Reinhold Graf
    Bert Hildebrandt
    Wolfgang Tilly
    Hanno Riess
    Roland Felix
    Volker Budach
    Peter Wust
    [J]. BMC Cancer, 6
  • [34] Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma
    Barone, C.
    Grillo, R.
    Dongiovanni, D.
    Birocco, N.
    Rampino, M.
    Redda, M. G. Ruo
    Garibaldi, E.
    Munoz, F.
    Pecorari, G.
    Cavalot, A.
    Garzinodemo, P.
    Buffoni, L.
    Ciuffreda, L.
    Ricardi, U.
    Cortesina, G.
    Giordano, C.
    Fasolis, M.
    Berrone, S.
    Bertetto, O.
    Schena, M.
    [J]. ANTICANCER RESEARCH, 2008, 28 (2B) : 1285 - 1291
  • [35] Chemotherapy in unresectable head and neck cancer - Reply
    Vermorken, Jan B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (10): : 1075 - 1075
  • [36] Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis
    Haussmann, Jan
    Tamaskovics, Balint
    Boelke, Edwin
    Djiepmo-Njanang, Freddy-Joel
    Kammers, Kai
    Corradini, Stefanie
    Hautmann, Matthias
    Ghadjar, Pirus
    Maas, Kitti
    Schuler, Patrick J.
    Hoffmann, Thomas K.
    Lammering, Guido
    Budach, Wilfried
    Matuschek, Christiane
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (12) : 1041 - 1049
  • [37] Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy
    Mencoboni, M.
    Grillo-Ruggieri, F.
    Salami, A.
    Scasso, F.
    Rebella, L.
    Grimaldi, A.
    Dellepiane, M.
    Moratti, G.
    Bruzzone, A.
    Spigno, F.
    Ghio, R.
    Figliomeni, M.
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2011, 20 (04) : 503 - 507
  • [38] IMPACT OF ADDING CONCOMITANT CHEMOTHERAPY TO HYPERFRACTIONATED ACCELERATED RADIOTHERAPY FOR ADVANCED HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
    Nuyts, Sandra
    Dirix, Piet
    Clement, Paul M. J.
    Poorten, Vincent Vander
    Delaere, Pierre
    Schoenaers, Joseph
    Hermans, Robert
    Van den Bogaert, Walter
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (04): : 1088 - 1095
  • [39] The End of TPF Induction for locally advanced Head and Neck Cancer? Induction Chemotherapy followed by Cetuximab and Radiotherapy is not superior to concurrent Chemoradiotherapy
    Hermann, R. M.
    Christiansen, H.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (03) : 281 - 284
  • [40] Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer
    Karasawa, K.
    Ito, K.
    Takada, T.
    Matsumoto, F.
    Haruyama, T.
    Ito, S.
    Ikeda, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S450 - S451